Molecular Glue vs PROTAC — Oncology Deal Terms Comparison
Market Analysis
In oncology, Molecular Glue and PROTAC represent two of the most actively transacted modalities. At Phase 2, Molecular Glue deals carry a median total deal value of $2.3B with $361M upfront, compared to $2.2B total value and $348M upfront for PROTAC. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Molecular Glue development milestones average $483M versus $466M for PROTAC. Commercial milestones are $676M for Molecular Glue and $652M for PROTAC. Royalty rates range from 13%-21.3% for Molecular Glue and 12.9%-21.1% for PROTAC.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Molecular Glue and PROTAC deal terms compare in oncology?
Which modality commands higher royalty rates: Molecular Glue or PROTAC?
How do milestone structures differ between Molecular Glue and PROTAC?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.